Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

Rhea-AI Summary

Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of Canadian Patent #3,024,728 for its Linebacker™ technology platform. The patent, titled "Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders," covers novel enhanced phenolic compounds and pharmaceutical compositions for treating inflammatory diseases.

The Linebacker™ technology targets key inflammatory pathways, potentially reducing inflammation and providing symptomatic relief with fewer side effects compared to traditional anti-inflammatory medications. The patent includes a method for using Linebacker™ formulations to inhibit inflammatory responses in conditions such as arthritis, asthma, and inflammatory bowel disease.

This is the first Linebacker™ patent issued in Canada, with an expiration date in May 2037. CEO Frank D. Heuszel highlighted the significance of this achievement, noting that the Canadian Inflammatory Disease Treatment Market was estimated at $7B in 2022.

Positive

• Issuance of Canadian Patent #3,024,728 for Linebacker™ technology
• Patent covers novel compounds and compositions for treating inflammatory diseases
• Potential for reduced side effects compared to traditional anti-inflammatory medications
• First Linebacker™ patent issued in Canada, expiring in May 2037
• Strengthens company's IP portfolio in a market estimated at $7B in 2022

Negative

• None.

HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker™ technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 entitled “Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders". This patent includes claims to novel enhanced phenolic compounds and pharmaceutical compositions as well as their uses in treating inflammatory related diseases.

The Linebacker™ technology is a platform of small molecule compounds, which target key pathways in the inflammatory process, potentially reducing inflammation and providing symptomatic relief while reducing side effects often associated with traditional anti-inflammatory medications.

This patent also employs a method of using a Linebacker™ formulation of novel compounds, with potential to inhibit the inflammatory response and mitigate conditions such as arthritis, asthma, and inflammatory bowel disease. This marks the first Linebacker™ patent issued in Canada, emphasizing Impact BioMedical’s commitment to discovering, developing, and patenting unique technologies to address unmet needs in human healthcare. The term of this Canadian patent will expire in May 2037.

Frank D. Heuszel, CEO of Impact BioMedical, commented, "The Canadian Inflammatory Disease Treatment Market was estimated to be $7B in 2022 according to Precedence research. This patent issuance strengthens our growing IP portfolio and underscores the innovative nature and commercial and therapeutic potential of our Linebacker™ technology.”

About Impact BioMedical Inc.:
Impact BioMedical Inc. (“IBO”) discovers, confirms, and patents unique science and technologies resulting in new offerings in human healthcare and wellness. Once available, IBO works closely with licensing, co-development, joint ventures, and other relationships to bring these offerings to market. For more information, visit Impact BioMedical Inc. | Reverse Engineering Nature (impactbiomedinc.com).

About Linebacker™ : Linebacker™ is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Polyphenols are substances found in many nuts, vegetables, and berries. Linebacker™ compounds are modified myricetin, which is a common plant-derived flavonoid. Linebacker™ down-regulates PIM (proviral integration site for Moloney murine leukemia virus) kinase which plays a key role as an oncogene in solid tumor cancers. Composition and method patents are issued for Linebacker™ in the U.S. and other countries. Linebacker™ -1 and Linebacker™ -2 compounds have been licensed to ProPhase Laboratories for development and commercialization worldwide. Linebacker™ is a trademark of Impact BioMedical Inc.

Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Investor Relations:
info@impactbiomedinc.com

        

FAQ

What is the new Canadian patent issued to Impact BioMedical Inc. (IBO) for?

Impact BioMedical Inc. (IBO) has been issued Canadian Patent #3,024,728 for its Linebacker™ technology platform, which covers novel enhanced phenolic compounds and pharmaceutical compositions for treating inflammatory related diseases and disorders.

When does Impact BioMedical's (IBO) new Canadian patent for Linebacker™ technology expire?

The Canadian patent for Impact BioMedical's (IBO) Linebacker™ technology will expire in May 2037.

What conditions could Impact BioMedical's (IBO) Linebacker™ technology potentially treat?

Impact BioMedical's (IBO) Linebacker™ technology has the potential to inhibit inflammatory responses and mitigate conditions such as arthritis, asthma, and inflammatory bowel disease.

What was the estimated size of the Canadian Inflammatory Disease Treatment Market in 2022, according to Impact BioMedical (IBO)?

According to Impact BioMedical (IBO), citing Precedence research, the Canadian Inflammatory Disease Treatment Market was estimated to be $7 billion in 2022.